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MacaqueHuman immunodeﬁciency virus-1 (HIV-1) and simian immunodeﬁciency virus (SIV) have been shown to
compartmentalize within various tissues, including the brain. However, the evolution of viral quasispecies in
the setting of drug abuse has not been characterized. The goal of this study was to examine viral evolution in
the cerebral compartment of morphine-dependent and control macaques to determine its role in rapid
disease progression. To address this issue, we analyzed the envelope (env) gene from proviral DNA in our
SIV/SHIV macaque model of morphine dependence and AIDS. Analyses of proviral DNA revealed a direct
correlation between total genetic changes and survival time. However, the rate of evolution during disease
progression was higher in morphine-dependent and rapid-progressor macaques than was the rate of
evolution in the control animals. This study provides additional insight into SIV envelope variation in the CNS
of morphine-dependent macaques and genotypes that may have evolved in the brain and contributed to
disease progression.
© 2009 Elsevier Inc. All rights reserved.Introduction
Drug abuse and dependence are widespread in the general
population in many parts of the world and intravenous drug use is
thought to play a major role in spread of the human immuno-
deﬁciency virus-1 (HIV-1) through engagement in a number of high-
risk behaviors, including sharing needles and sexual contact.
The occurrence of HIV-1 infection in the context of drug abuse
raises important questions about the potential interactions between
the two phenomena. This is particularly signiﬁcant considering that a
large proportion of drug abusers are also HIV-1-infected individuals
(2002; 2003; Alcabes and Friedland, 1995; Chu and Levy, 2005; Cohn,
2002; Des, 1999). As of 2006, the Centers for Disease Control had
estimated that there were 540,436 deaths in the United States of
persons with AIDS, of which approximately 28% of the total were
injection drug users (IDUs) (Centers for Disease Control and
Prevention, 2008). The most widely abused drugs in the United
States include heroin, cocaine and methamphetamine. However, the
majority of IDUs report using multiple drugs at different times, thus it
is difﬁcult to directly link a speciﬁc drug to the observed clinical health
parameters. Althoughnumerous studies havedocumented thatHIV-1-
infected IDU experience substantial pre-AIDS morbidity, the naturalll rights reserved.history and progression of HIV-1 infection among IDU remains
uncertain. Regardless, both in vitro and in vivo studies have
demonstrated a correlation between drugs of abuse and increased
viral replication (Chuang et al., 1993; Nyland et al., 1998; Guo et al.,
2002; Suzuki et al., 2002; Kumar et al., 2006).
HIV-1 and simian immunodeﬁciency virus (SIV) infections lead to
neurological complications, and drug abuse is thought to adversely
affect this occurrence in humans. Although antiretroviral therapy has
proven effective in reducing the viral load in the central nervous
system (CNS) with a resulting improvement in neurological function,
viral reservoirs persist in the brain (reviewed in: (Dunfee et al., 2006).
Understanding viral evolution in the brain will help determine the
viral factors that contribute to neurological disease.
The SIV/macaque model is particularly valuable for evaluating
information that is usually impossible to obtain from human studies,
such as the genotypic and phenotypic properties of the infecting virus,
knowledge of the exact time of virus exposure, assessment of disease
progression, and the characteristics of viral variants in the infected
host. Whereas compartmentalization has been well demonstrated for
both HIV-1 and SIV, few studies have characterized the impact of
drugs of abuse on the degree of SIV env evolution and the role such
viral dynamics may play in the rate of disease progression. Our model
of SIV/ SHIV infection and drug abuse offers a unique opportunity to
address these important questions. We have previously shown a
negative correlation between evolution of viral accessory genes in
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progression (Noel and Kumar, 2007; Noel et al., 2006; Tirado and
Kumar, 2006; Noel and Kumar, 2006). In addition, we have also shown
a positive correlation between the evolution of virus envelope and
opiate-mediated disease progression (Rivera-Amill et al., 2007). In
this study we wanted to investigate the pathogenic and biologic
consequences of SIV envelope sequence variation within the brain in
morphine-dependent and control macaques infected with SIV/SHIV.
In this report, the sequences of SIV/17E-Fr envelope gene recovered
from the brain of morphine-dependent macaques are described. The
results indicate that the highest levels of nucleotide substitution in
sequences isolated from the brain were observed in animals that
survived for longer periods, regardless of whether they were
morphine dependent or not. Although the total diversity was most
closely related to duration of infection, the rate of evolution was
fastest for the morphine-dependent rapid disease progressors, who
showed a rapid accumulation of changes early during infection.
Results
Clinical disease parameters of the six morphine-dependent and
three control macaques used in this study are shown in Table 1. Half of
the morphine-dependent macaques developed rapid disease progres-
sion (1/04L, 1/42N and 1/28Q). These macaques maintained high
viral loads both in plasma and CSF, and low CD4+ T cell counts. In
contrast,morphine-dependent normal progressors (1/56L, 1/02N and
1/52N) and control macaques (2/02P, 2/AC42 and 2/31P) exhibited
lower viral loads, and higher CD4+ T cell counts. Two normal
progressors and two control macaques exhibited CSF viral loads
below the level of detection (Table 1). In order to determine whether
viral DNA persisted in thesemacaques, genomic DNA frombrain tissue
was isolated and used for Real Time PCR to quantitate SIV/17E-Fr in
the brain. Using env speciﬁc primers and probe, we demonstrated the
presence of SIV/17E-Fr in the brain tissue from morphine-dependent
and controlmacaques despite signiﬁcant down-regulation of viral RNA
in the CSF (Table 1). Viral DNA in the brains of morphine-dependent
and control animals was detected at similar levels and there were no
statistically signiﬁcant differences among the groups. These results,
are in agreementwith a previous study of SIV encephalitis by Clements
et al. (2002), where they revealed that despite signiﬁcantly lower
levels of viral RNA in the brain after the acute phase, the DNA levels
remained constant. Therefore, even though viral load in the CSF of twoTable 1
Summary of clinical data.
Macaque Survivala
(weeks, pi)
CD4+ T cellsb Viral load
(×104 RNA copies/ml)
Plasma CSF
Morphine-
Rapid
1/04L 18 2.9 3340 226
1/42Nd 19 10 10700 111
1/28Qd 20 6 7660 166
Normal
1/56Ld 51 23 436 382
1/02N 161 43 2.87 ND
1/52N 161 160 NDe ND
Control
2/02P 60 42 2.56 1.6
2/AC42 64 67 0.038 ND
2/31P 147 503 0.236 ND
a A monkey surviving b24 weeks after infection was considered a rapid disease progress
b CD4+ T cells are presented as number/ ml of blood at the time of necropsy.
c SAIDS: Simian AIDS.
d The animal developed neurological disorders.
e Not detectable. The viral load was b20 RNA copies/ml.
f Not done.morphine-dependent normal progressors and two control macaques
at the time of death were below the level of detection, virus-infected
cells were not cleared. We were able to detect SIV RNA in brain tissue
albeit at low levels and there were no signiﬁcant differences between
morphine dependent and control macaques (Table 1). Pathological
changes in the brains of morphine-dependent macaques with
neurological symptomswere characterized by accumulation ofmacro-
phages in the perivascular region (Fig. 1A), focal histiocytic nodules
(Fig. 1B) and multi-nucleated giant cells (Fig. 1C), characteristic of
lentiviral encephalitis. Nextwe analyzed the SIV/17E-Fr env gene from
the DNA isolated frommorphine-dependent and control macaques in
order to determine whether there are remarkable differences in the
viruses that had established in the brain. Based on our previous study
(Rivera-Amill et al., 2007), we focused this analysis on SIV env V3-V5.
In the present study we analyzed the diversity, divergence, synony-
mous and non-synonymous substitutions, as well as amino acid
mutations in key functional regions in order to characterize SIV env
evolution within the CNS.
Phylogenetic analysis of env clones from brain tissue
Phylogenetic analyses using SIV env V3V5 sequences derived from
genomic brain DNA were carried out to determine the relatedness of
variants between morphine-dependent and control macaques. Five to
ten clones from eachmacaque were sequenced, aligned and subjected
to phylogenetic analysis using the distance-based (neighbor-joining)
method. The SIV/17E-Fr env sequence was used as the root for the
trees. Bootstrap resampling using 500 replicate trees was carried out
to estimate the robustness of the observed groupings. Phylogenetic
trees of the morphine-dependent and control macaque brain-derived
clones revealed clustering of the majority of the sequences derived
from rapid progressors and a mixed distribution for some of the
sequences derived from normal progressors and control macaques
(Fig. 2). Greater branch lengths were observed in the phylogenetic
reconstruction for morphine-dependent normal progressors and
control macaques, whereas rapid progressors exhibited less clonal
diversity. When taking into consideration the average survival time
for each group (rapid progressors 19 weeks; normal progressors
124 weeks; control macaques 90 weeks), we ﬁnd that the rapid
progressors exhibited a higher rate of mutations as compared to the
other groups and that the sequences isolated from this group appear
ancestral to the sequences isolated from the other macaques.Brain proviral load
(×103 copies/μg of DNA)
Brain RNA viral load
(×102 copies/μg of RNA)
SAIDSc
0.007 12.3 +
0.003 7.38 +
0.001 4.93 +
0.0002 4.13 +
e 0.03 NDf −
e 0.0001 4.75 −
7 0.00003 5.0 +
e 0.0005 4.98 +
e 0.0001 5.34 −
or.
Fig. 1. Pathological changes inmorphine-dependent rapid progressor with neurological
symptoms. Immunohistochemical analyses were performed on parafﬁn-embedded
tissues from macaque 1/28Q as described in Materials and methods. Panels: A,
accumulation of macrophages in the perivascular region; B, focal histiocytic nodules; C,
multi-nucleated giant cells.
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We next calculated the nucleotide diversity of env V3–V5 region
frombrain samples focusing on group average calculations usingMEGA
3.1. Therewas no signiﬁcant difference in overall diversity between the
clones derived from rapid and normal morphine-dependent and
control macaques. However, analysis of the divergence from the
inoculum revealed a statistically signiﬁcant difference between rapid
progressors and controlmacaques,whereas nodifferencewas detected
when comparing normal progressors to either rapid progressors or
control macaques (Fig. 3). When focusing exclusively on the V4 loop
subregion, however, therewas a signiﬁcant reduction in the divergence
of the brain-derived sequences from rapid progressors as compared toFig. 2. Boostrap Neighbor-Joining trees of env V3-V5 sequences. Envelope sequences
were obtained from brain tissue of morphine-dependent rapid progressors (open
circles), morphine-dependent normal progressors (closed circles) and control maca-
ques (diamonds) infected with SIV/17E-Fr, SHIVKU-1B and SHIV89.6P. The phylogenetic
trees were generated using theMEGA 3.1 program and boostrap values were performed
on 500 replicates and those N50 are indicated at the nodes. Nodes where no value is
indicated were not supported at this level. The trees were rooted using the
corresponding sequence from SIV/17E-Fr (black square).
Fig. 3. Viral molecular diversity and divergence of brain-derived env V3-V5 sequences
obtained from morphine-dependent and control macaques infected with SIV/17E-Fr,
SHIVKU-1B and SHIV89.6P. The proviral env sequences were aligned and used to calculate
diversity and divergence using MEGA 3.1. The mean percent diversity and divergence
are plotted for each group. Error bars indicate standard error.
Fig. 5. Rate of substitution at synonymous and non-synonymous sites. SIV env V3-V5
nucleotide sequences isolated from brain tissue of morphine-dependent and control
macaqueswere compared to the sequence of the startingmolecular clone of SIV/17E-Fr.
The numbers of nucleotide changes leading to synonymous (dS) and non-synonymous
(dN)mutations were tallied using SNAP, www.hiv.lanl.gov. Error bars indicate standard
deviation.
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diversity of the clones did not differ when comparing the groups.
Previously, we found a direct correlation between SIV envV4 evolution
and rapid disease progression when analyzing env sequences CSF by
12 weeks post-infection (wpi) (Rivera-Amill et al., 2007). By 18 wpi,
the morphine-dependent macaques still exhibited greater diversity
and divergence as compared to control macaques. However, the
morphine-dependent normal progressors had started to exhibit an
increase in divergence as compared to rapid progressors. When
analyzing sequences from the morphine-dependent normal progres-
sors at a later time point, 32 wpi, we found that both the diversity and
divergence (1.73% and 1.30%, respectively) of the clones from
morphine-dependent normal progressors were higher than at 18 wpi
although this difference was not signiﬁcant.
Synonymous and non-synonymous nucleotide substitution rates
We analyzed the relative rates of synonymous (dS) and non-
synonymous (dN) nucleotide substitutions in env V3V5 to assess
selectionpressures between the groups. For all of the samples analyzed,
the dN rates were lower than the dS rates suggesting that positive
selection did not play a role as the force driving the evolution of the env
gene and that therewas a bias toward silent substitutions in this region
of env (Fig. 5). Morphine-dependent rapid progressors exhibited
signiﬁcantly fewer silent and non-silent substitutions when compared
to both morphine-dependent normal progressors and control maca-Fig. 4. Viral molecular diversity and divergence of brain-derived env V4 sequences
obtained from morphine-dependent and control macaques infected with SIV/17E-Fr,
SHIVKU-1B and SHIV89.6P. The proviral env sequences were aligned and used to calculate
diversity and divergence using MEGA 3.1. The mean percent diversity and divergence
are plotted for each group. Error bars indicate standard error of the mean.ques, supporting the idea that positive selection forces were not
distinct among rapid progressors. In contrast, there was no signiﬁcant
difference between the normal progressors and control macaques.
Genotypic analysis of env regions
SIV env V3V5 brain sequences were compared for their differences
in the number of positively charged amino acid residues in the V3, V4,
V5 loops and changes within the GGDPE motif of the CD4 binding
region. The net charge of each region was calculated by subtracting
the number of negatively charged amino acids from the number of
positively charged amino acids. Analysis of the amino acid changesFig. 6.Mean frequency of amino acid mutations and net charge changes within the V4
loop from brain sequences of morphine-dependent and control macaques infected with
SIV/17E-Fr, SHIVKU-1B and SHIV89.6P. Panel A, the mean frequency of amino acid
mutations was calculated as the total number of mutations in monkey divided by the
number of clones. Represented are the averages of mutations per group. Panel B, the net
charge of the V4 loop was calculated by subtracting the number of negatively charged
amino acids from the number of positively charged amino acids. Represented are the
averages of the net charge per group. Error bars indicate standard deviation.
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morphine-dependent and control macaques revealed no signiﬁcant
differences in the frequency of amino acid mutations and overall
changes in the net charge for any of the groups (data not shown).
Within the V4 loop (Fig. 6), morphine-dependent macaques exhibited
a slight decrease in both the frequency of amino acid mutations (1.29)
and the overall charge (2.85) as compared to control macaques that
exhibited higher frequency of amino acid mutations (2.24) an
increase in the overall charge within this region (3.19). However,
this difference was only signiﬁcant when comparing morphine-
dependent rapid progressors and control macaques.
As shown in Fig. 7, the mean frequency of amino acid mutations
within the GGDPE motif was lower for the rapidly progressing
morphine-dependent macaques as compared to normal progressors
and controls. However, this difference was signiﬁcant only when
comparing rapid progressors to control macaques. Analysis of the
changes of the net charge within this motif revealed that the rapid
progressors maintained a higher overall negative charge as compared
to normal progressors and control macaques for which most of the
clones had a D385G change within this region. Analysis of previously
reported sequences from CSF revealed that the rapid progressors
demonstrated a similar frequency of amino acid mutations (0.326) as
was seen in brain samples (Rivera-Amill et al., 2007). However, the
normal progressors and controls exhibited a lower frequency of
amino acid mutations by 18 wpi (0.704 and 0.067, respectively) than
was observed in the brain samples. Interestingly, in plasma-derived
sequences, changes within this motif were detected in rapid disease
progressors at a high frequency, whereas in morphine-dependent
normal progressors and control macaques very few clones exhibited
changes in this region. In contrast to the normal progressors and control
macaques, the rapid disease progressors were unable to mount a
neutralizing humoral response (Kumar et al., 2006). Collectively, theseFig. 7. Mean frequency of amino acid mutations and net charge changes within the
GGDPE motif from brain sequences of morphine-dependent and control macaques
infected with SIV/17E-Fr, SHIVKU-1B and SHIV89.6P. Panel A, the mean frequency of
amino acid mutations was calculated as the total number of mutations in monkey
divided by the number of clones. Represented are the averages of mutations per group.
Panel B, the net charge of the GGDPEmotif was calculated by subtracting the number of
negatively charged amino acids from the number of positively charged amino acids.
Represented are the averages of the net charge per group. Error bars indicate standard
deviation.data suggest that changes within this region occurred independently of
selective pressures from the immune system.
A D385N change has been reported from SIVmac239-infected
animals that progressed rapidly to simian AIDS (SAIDS) and this
change, in addition to G383R which is frequently found together with
D385N, resulted in a greater decrease in CD4 binding (Ryzhova et al.,
2002). None of the SIV/17E-Fr clones reported here exhibited the
G383R change. Conversely, even though these changes were found to
be associated with enhancement of CD4-independent cell to cell
fusion, it has been reported that analysis of individual changes in
SIVmac239 D385N or D385G result in decreased viral infectivity (Otto
et al., 2003), suggesting that additional changes must also be selected
for efﬁcient viral replication and spread.
Discussion
In this study, the morphine-dependence SIV/SHIVmacaquemodel
was used to investigate SIV env sequence variation in the brain
because macaques are common models for Neuro-AIDS. The use of a
cocktail ofmolecularly cloned viruses allowed for the closemonitoring
of viral genetic variation. The changes within SIV env V3V5 region in
brain were examined in six morphine-dependent and three control
macaques that were all infected with SIV/17E-Fr, SHIVKU-1B and
SHIV89.6P to understand the evolution of viral genes and their
contribution to disease progression and neurological disease.
A number of studies have focused on in vivo SIV env evolution in
both rapid and slow disease progressors. Despite the fact that rapid
progressors exhibit an apparent lack of immune pressure due to the
absence or transience of humoral and cellular immune responses and
they maintain high viral loads throughout infection, SIV env under-
goes unique changes within this group. Although the details of the
animal model used were different as compared to the present study,
in a report by Chen et al. (2006), analysis of SIVmac239 env evolution
in the central nervous system (CNS) revealed that long-term
progressing macaques demonstrated a greater degree of compart-
mentalization and higher synonymous and non-synonymous substi-
tution rates as compared to the rapidly progressing macaques.
However, in their study they were unable to analyze sequential
plasma or CSF samples to determine how the changes were
accumulating. In contrast, in a study by Dehghani et al. (2003), the
investigators reported that substitutions within the V3 loop and
GGDPE motif of SIVsmE543-3 characteristic of all rapid progressors
studied were not observed in slow progressors by 52 wpi. At later
times post-infection they determined that in rapid progressors, virus
variants appear to be adapted to replicate in vivo but are at a
disadvantage to replicate in tissue culture as compared to the parent
strain (Kuwata et al., 2006). However, samples from the slow
progressors taken near the time of death were not reported in these
studies. Thus it remains unclear as to whether the changes in env
could have accumulated at a later time point in slow progressors.
Other studies have also focused on SIV env evolution but have not
distinguished between animals with different rates of disease
progression (Kinsey et al., 1996). It should be emphasized that none
of the studies reported drug abuse as a confounding factor.
In our earlier analysis of SIV env evolution in plasma and CSF, we
found direct correlation of SIV env V4 region and disease progression
at 12 wpi, i.e. the morphine-dependent rapid progressors exhibited
more diversity and divergence of the clones than morphine-
dependent normal progressors and control macaques (Rivera-Amill
et al., 2007). By 18 wpi, the normal progressors exhibited a higher
trend of divergence as compared to the rapid progressors although
this difference was not signiﬁcant. Both morphine-dependent sub-
groups exhibited increased diversity and divergence as compared to
control macaques. Analysis of viral diversity and divergence within
the morphine-dependent normal progressors at a later time point, 32
wpi, revealed that the normal progressors exhibited a diversity of
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of statistical signiﬁcance, than the last time point recorded for the
rapid progressors (unpublished data). We were unable to amplify SIV
env from control macaques at 32 wpi. In this study, we analyzed SIV
proviral env evolution in brain tissue. When comparing the rapid
progressor brain sequences to plasma and CSF sequences from the
time of death, like before, we found a signiﬁcant difference between
plasma and brain. No signiﬁcant differences were detected in the
diversity and divergence when comparing brain and CSF isolated
sequences, indicating that the actively replicating viral forms detected
in the CSF of rapid disease progressors were from the viral forms
established in the brain. However, when including in the analysis
samples from morphine-dependent normal progressors and control
macaques, we found an inverse correlation between sequence
diversity and disease progression, i.e. the rapid progressors exhibited
less diversity and divergence in brain isolated sequences as compared
to morphine-dependent normal progressors and control macaques.
Althoughwewere unable to amplify SIV fromplasma and CSF samples
from morphine-dependent and control macaques near the time of
death (viral loads were below the level of detection), as explained
above, the trend was that the macaques that survived longer
demonstrated an increase in both diversity and divergence as
compared to the rapidly progressing macaques. Thus, sequence
changes were accumulating at a faster rate in morphine-dependent
rapid progressors as compared to morphine-dependent normal
progressors and control macaques. These results suggest that the
genetic variation observed in the brain sequences from morphine-
dependent normal progressors and control macaques was a conse-
quence of the difference in length of survival rather than a result of a
higher rate of accumulation of mutations and perhaps morphine does
not alter selection but only quickens evolution initially as seen in
rapid progressors. Furthermore, our immunohistochemical ﬁndings
also suggest evidence of increased dissemination of virus in various
peripheral tissues (data not shown) with concomitant neuropatho-
logical changes in the morphine-dependent animals.
Current work is in progress in our laboratory to address whether
these observations correlate with the analysis of SIV env evolution in
other compartments as well as the functional characterization of
these changes. Work is also underway to determine whether other
genotypes are also present in the brain. Further studies are needed to
deﬁne the role of env and other viral genes in the development of
rapid disease progression and neuroAIDS in the setting of drug abuse.
Materials and methods
Animal model
Establishment ofmorphine addiction has been previously described
(Kumar et al., 2004a). Brieﬂy, morphine dependence was established
by injecting increasing doses ofmorphine (1 to 5mg/kgof bodyweight
over a 2-week period) by the intramuscular route at 8-h intervals. The
animals were maintained at three daily doses of morphine (5 mg/kg)
for an additional 18 weeks. All macaques were infected by the
intravenous route with a 2-ml inoculum containing 104 50% tissue
culture infective doses each of simian-human immunodeﬁciency virus
SHIVKU-1B (Singh et al., 2002), SHIV 89.6P (Reimann et al., 1996a, 1996b)
and SIV/17E-Fr (Flaherty et al., 1997). All animalswere perfused before
euthanasia to remove PBMCs. The experimental protocolwas approved
by the Institutional Animal Care and Use Committee, and the research
was conducted in accordance with the Guide for the Care and Use of
Laboratory Animals.
Viral RNA in plasma and CSF
Cell-free viral loads in plasma and CSF were determined in
duplicate by real-time reverse transcription-PCR (RT-PCR) (Amaraet al., 2001). The viral RNA copy number in macaque samples was
determined by comparisonwith an external standard curve consisting
of in vitro transcripts from the SIVmac239 genome. This assay has a
sensitivity of 80 copies/ ml of plasma or CSF.
Immunohistochemical staining
Immunohistochemical analyses were performed on parafﬁn-
embedded tissues. Parafﬁn embedded tissue sections were depar-
afﬁnized in xylene for 30 min and rehydrated in graded series of
alcohol. Following washes in PBS and blocking in donkey serum for
30 min, sections were incubated in primary murine monoclonal
antibodies to p27, the Gag protein of SIV (Advanced Biotechnologies
Inc, Maryland, USA); followed by treatment with biotinylated goat
anti-mouse IgG (DAKO, Carpenteria, California, USA), peroxidase-
conjugated streptavidin (DAKO), and NovaRed substrate (Vector
Laboratories, Burlingame, California, USA), which yields a reddish
reaction product (Hicks et al., 2002). Cells positive for p27 were
counted using a 40× objective. For each sample, 70 different ﬁelds
were evaluated and the number of positive cells was calculated for the
total area of the ﬁelds.
Tissue collection and processing
Tissue specimens were obtained from our archived collection of
rhesusmacaque tissues at Ponce School of Medicine. DNA from tissues
was isolated using the QIAmp DNA Blood and Tissue Kit (Qiagen, Inc.,
Valencia, CA) according to the manufacturer's recommendations.
Viral DNA and RNA in brain tissue
To quantitate viral DNA and RNA in brain tissue, genomic DNA and
total RNA were isolated from duplicate samples of frozen tissue using
DNeasy Tissue Kit and RNeasy kit (Qiagen, Inc., Valencia, CA),
respectively, following the directions of the manufacturer. SIV/17E-
Fr proviral and RNA viral loads were quantitated by use of envelope
speciﬁc primers and probes in a real-time PCR and real time RT-PCR
assays. Each sample was quantitated in duplicate and the experiment
was performed two times; the sensitivity of detection was 5 copy
equivalents/μg of total brain DNA or RNA. The primers and probe for
SIV/17E-Fr were the following: forward 5′-CAG CAT CAG CAA GAG
TAG ACA TG-3′; reverse 5′-CAA GCC TGC GCA ATT ATC C-3′; probe:
5′-/56-FAM/ TCA ATG AGA CTA GTT CTT GTA TAG CCC/ 3BHQ_1/-3′.
The real time PCR cycling was as follows: 1×95.0 °C for 15 min; 45×
(95.0 °C for 15 s, 55.0 °C for 1 min) data collection and real-time
analysis enabled at 60.0 °C. For real time RT-PCR an additional step at
50.0 °C for 30 min was added.
Ampliﬁcation, cloning and sequencing of V3-V5 regions of env
A 905-bp fragment of the env region of SIV/17E-Fr was ampliﬁed
as previously described (Rivera-Amill et al., 2007). The fragment was
conﬁrmed by agarose electrophoresis prior to cloning into pCR2.1
using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA). Positive
clones were identiﬁed by colony screening with restriction enzyme
digest (EcoRI, Promega) and agarose electrophoresis. Plasmid prepa-
ration was performed using the standard protocol of Qiagen Qiaprep
Spin Mini Kit. primer set as described above. Clones were sequenced
using the M13 forward site on pCR2.1 by the DNA Sequencing Facility
of Molecular Cloning Laboratories, South San Francisco, USA.
Sequence analysis and statistics
All sequence ﬁles were ﬁrst manually veriﬁed and edited as
necessary using the software ChromasLite 2.0 (Technelysium Pty Ltd,
Australia). Edited sequences were aligned using BioEdit version
207V. Rivera-Amill et al. / Virology 398 (2010) 201–2077.0.5.2 (Hall, 2006) and Clustal W (Thompson et al., 1994). The Clustal
W program (runs within BioEdit) was set to perform multiple
sequence alignments using the default penalties. Aligned sequences
were used to calculate viral nucleotide diversity using the method of
Kimura-2 parameter in the program MEGA 3.1(Kumar et al., 2004b).
This same method was used to quantify nucleotide divergence from
the source. Phylogenetic trees were constructed using the program
MEGA version 3.1. All phylogenetic analyses used the SIV/17E-Fr
inoculum sequence as a reference. The cumulative number of synony-
mous and non-synonymous substitutions was estimated using
Synonymous/Nonsynonymous Analysis (SNAP; http://hiv-web.lanl.
gov), which calculates rates of nucleotide substitution from a set of
codon aligned nucleotide sequences, based of the method of Nei and
Gojobori (Nei and Gojobori, 1986). Statistical comparisons were done
using a two-tailed t-test. The statistical cut-off for signiﬁcance in these
analyses was p=0.05.
Nucleotide sequences
Sequences in this report are available from GenBank with
accession numbers from GQ290222 to GQ290297.
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